Weight-loss drug deals to drive around 4% of Gerresheimer yearly growth, CEO says
By Patrick Wingrove (Reuters) – Gerresheimer CEO Dietmar Siemssen said he expects about 4% of the company’s revenue growth per year from deals to supply makers of drugs for weight loss and diabetes with vials, cartridges, syringes and autoinjectors. The German company reported in February that it expects to grow an average of 10% per …
Weight-loss drug deals to drive around 4% of Gerresheimer yearly growth, CEO says Read More »










